Urban air pollution contributes to premature mortality and adverse respiratory outcomes. Policies that restrict polluting vehicles aim to reduce exposures, but causal evidence on health-related outcomes from such policies is limited. This preprint evaluates the impact of all three stages of London’s Ultra Low Emission Zone (ULEZ) on ambient fine particulate matter (PM2.5) and on primary care prescribing for respiratory disease, using general practice–level data and a causal inference design.
Analyses were conducted at the general practice level using a generalised synthetic control method to estimate causal impacts of each ULEZ stage. Air quality was assessed using PM2.5 levels. Respiratory health was proxied by prescribing records for two medication classes: bronchodilators and inhaled corticosteroids. Outcomes included total quantity prescribed and average daily quantity (ADQ) where reported.
All patient-level data were publicly available and the authors report that data sources and code are accessible via the data bibliography. Cited data repositories include English prescribing data from NHS Digital, Public Health England Fingertips, the GP Quality and Outcomes Framework (QOF), and Transport for London Freedom of Information responses. The manuscript is a preprint and has not been peer reviewed.
The study reports small, stage-specific changes in PM2.5 associated with the ULEZ interventions. Stage 1 was associated with a statistically significant but negligible 0.77% reduction in PM2.5. Stage 2 was associated with a 2.69% increase in PM2.5, described by the authors as paradoxical. Stage 3 produced a 2.69% reduction in PM2.5. Overall, the authors characterise these changes as minimal in magnitude and inconsistent across stages.
Prescribing outcomes varied by ULEZ stage and drug class. For Stage 1, there was no corresponding change in prescribing at the general practice level despite the small PM2.5 reduction.
During Stage 2, the authors observed mixed respiratory prescribing signals: a 4.44% decrease in inhaled corticosteroid total quantity but a 12.51% increase in inhaled corticosteroid ADQ. The authors interpret this pattern as potentially indicating worsening disease severity among existing patients (higher per-patient daily use) rather than an increase in the number of patients receiving corticosteroids.
Stage 3 was associated with a modest 2.18% decrease in bronchodilator ADQ usage. No large or consistent reductions in prescribing across drug classes were identified that would indicate a clear public health benefit from the ULEZ stages measured.
Analyses detected statistically significant spillover effects of the ULEZ outside the zone boundary; however, the magnitude of these spillover effects was described as negligible. The authors therefore treat spillover as measurable but not clinically meaningful in the context of their outcomes.
The study concludes that the ULEZ produced minimal effects on both ambient PM2.5 and on primary-care respiratory prescribing across the three staged implementations. Given the small and inconsistent changes reported, the authors suggest that the ULEZ alone may not be sufficient to deliver meaningful respiratory health gains at the population level.
They further suggest that integration of ULEZ-type measures with broader policy interventions may be necessary to achieve substantial improvements in air quality and consequent health outcomes. The paper positions its findings as providing new, causally informed insight that the ULEZ’s effects are smaller than some prior estimates.
The manuscript is a preprint and has not undergone peer review. Details specific to model specification, covariates used in the generalised synthetic control method, and sensitivity analyses are not reported in the abstract; readers should consult the full manuscript and data/code links for those elements. All data analysed are reported to be publicly available from NHS Digital prescribing datasets, Fingertips, the GP Data Hub (QOF), and Transport for London FOI responses; links are provided in the data availability statement.
Using a synthetic control approach at general practice level, the authors report that London’s ULEZ produced only minimal and inconsistent changes in PM2.5 and respiratory prescribing across three stages. Stage-specific findings include a small PM2.5 reduction after Stage 1 with no prescribing change, a paradoxical PM2.5 increase and mixed corticosteroid prescribing signals after Stage 2, and a modest PM2.5 reduction with a small bronchodilator ADQ decrease after Stage 3. The authors conclude that ULEZ effects on air quality and respiratory prescribing appear considerably smaller than previously reported and that broader policy integration may be needed to obtain meaningful public health benefits.